Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia.
Administration, Inhalation
Adrenal Cortex Hormones
/ therapeutic use
Bronchodilator Agents
/ therapeutic use
Bronchopulmonary Dysplasia
/ drug therapy
Caffeine
/ therapeutic use
Diuretics
/ therapeutic use
Female
Humans
Infant, Newborn
Infant, Premature
Insulin-Like Growth Factor I
/ therapeutic use
Mesenchymal Stem Cell Transplantation
Nitric Oxide
/ therapeutic use
Oxygen Inhalation Therapy
Phosphodiesterase 5 Inhibitors
/ therapeutic use
Phosphodiesterase Inhibitors
/ therapeutic use
Pregnancy
Prenatal Care
Progesterone
/ therapeutic use
Progestins
/ therapeutic use
Pulmonary Surfactants
/ therapeutic use
Sildenafil Citrate
/ therapeutic use
Vitamin A
/ therapeutic use
Vitamins
/ therapeutic use
Bronchopulmonary dysplasia
Chronic pulmonary insufficiency of prematurity
Lungs
Pharmacology
Journal
Clinics in perinatology
ISSN: 1557-9840
Titre abrégé: Clin Perinatol
Pays: United States
ID NLM: 7501306
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
entrez:
24
4
2019
pubmed:
24
4
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
Rates of bronchopulmonary dysplasia (BPD) are increasing. After preterm birth, there are important developmental periods in which neonates are more vulnerable to stressful events. These periods are opportunities for pharmacologic interventions. Many drugs remain inadequately tested and no new drugs have been approved in more than 25 years for BPD prevention or therapy. More progress is needed in defining appropriate end points based on the pathophysiology of BPD and postdischarge chronic pulmonary insufficiency of prematurity and to develop effective new drugs. In addition, much work is needed to better define perinatal factors, early postnatal findings, and physiologic phenotypes or endotypes.
Identifiants
pubmed: 31010561
pii: S0095-5108(19)30022-3
doi: 10.1016/j.clp.2019.02.011
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Bronchodilator Agents
0
Diuretics
0
Phosphodiesterase 5 Inhibitors
0
Phosphodiesterase Inhibitors
0
Progestins
0
Pulmonary Surfactants
0
Vitamins
0
Vitamin A
11103-57-4
Nitric Oxide
31C4KY9ESH
Caffeine
3G6A5W338E
Progesterone
4G7DS2Q64Y
Insulin-Like Growth Factor I
67763-96-6
Sildenafil Citrate
BW9B0ZE037
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
291-310Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.